NASDAQ:IMTX

Immatics (IMTX) Stock Forecast, Price & News

$9.87

+0.11 (+1.13%)

(As of 05/31/2023 ET)

Compare

Today's Range: $9.65
▼
$9.94
50-Day Range: $5.92
▼
$10.10
52-Week Range: $5.90
▼
$13.60

Volume: 107,496 shs
Average Volume: 315,510 shs
Market Capitalization: $756.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.75

Immatics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 100.1% Upside
$19.75 Price Target
Short Interest: Bearish
8.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.40
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.41) to ($1.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

944th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

156th out of 167 stocks

3.5

Analyst's Opinion

Consensus Rating
Immatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.75, Immatics has a forecasted upside of 100.1% from its current price of $9.87.
Amount of Analyst Coverage
Immatics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.05% of the float of Immatics has been sold short.
Short Interest Ratio / Days to Cover
Immatics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Immatics has recently increased by 28.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immatics does not currently pay a dividend.
Dividend Growth
Immatics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMTX.

2.4

News and Social Media Coverage

News Sentiment
Immatics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Immatics this week, compared to 1 article on an average week.
Search Interest
11 people have searched for IMTX on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immatics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 29.05% of the stock of Immatics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immatics are expected to decrease in the coming year, from ($1.41) to ($1.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immatics is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immatics is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immatics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immatics (NASDAQ:IMTX) Stock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Stock News Headlines

May 31, 2023 | americanbankingnews.com

Head to Head Contrast: Sangamo Therapeutics (NASDAQ:SGMO) and Immatics (NASDAQ:IMTX)

May 26, 2023 | finance.yahoo.com

Companies Like Immatics (NASDAQ:IMTX) Are In A Position To Invest In Growth

June 1, 2023 | Behind the Markets (Ad)

NOTICE: Your retirement is in immediate danger

Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>

May 23, 2023 | americanbankingnews.com

Head-To-Head Analysis: Curis (NASDAQ:CRIS) & Immatics (NASDAQ:IMTX)

May 21, 2023 | americanbankingnews.com

SVB Leerink Comments on Immatics' Q2 2023 Earnings (NASDAQ:IMTX)

May 18, 2023 | markets.businessinsider.com

Immatics (IMTX) Gets a Buy from Mizuho Securities

May 17, 2023 | markets.businessinsider.com

Jefferies Keeps Their Buy Rating on Immatics (IMTX)

May 16, 2023 | finance.yahoo.com

Immatics Announces First Quarter 2023 Financial Results and Business Update

June 1, 2023 | Vantage Point (Ad)

Instantly Find Hidden Trade Opportunities

There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.

May 5, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Immatics (IMTX)

May 5, 2023 | americanbankingnews.com

SVB Leerink Equities Analysts Increase Earnings Estimates for Immatics (NASDAQ:IMTX)

May 3, 2023 | msn.com

Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?

May 2, 2023 | finance.yahoo.com

What's Going On With Immatics Shares Today

May 2, 2023 | markets.businessinsider.com

US Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT Concerns

May 2, 2023 | msn.com

Immatics climbs 30% after early Phase 1 data for solid tumor therapy

May 2, 2023 | msn.com

Immatics Soars after Positive Clinical Update

May 2, 2023 | finance.yahoo.com

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

May 1, 2023 | markets.businessinsider.com

Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration

April 20, 2023 | americanbankingnews.com

Head to Head Review: Entera Bio (NASDAQ:ENTX) & Immatics (NASDAQ:IMTX)

April 19, 2023 | americanbankingnews.com

Immatics (NASDAQ:IMTX) Trading 7.1% Higher

April 16, 2023 | finance.yahoo.com

Immatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 42% of the company

April 8, 2023 | barrons.com

Immatics N.V.

April 5, 2023 | americanbankingnews.com

Immatics (NASDAQ:IMTX) Sees Unusually-High Trading Volume

April 1, 2023 | nasdaq.com

Mizuho Initiates Coverage of Immatics (IMTX) with Buy Recommendation

March 31, 2023 | msn.com

Immatics initiated Buy at Mizuho on underrated TCR opportunity

March 31, 2023 | americanbankingnews.com

Immatics (NASDAQ:IMTX) Coverage Initiated by Analysts at Mizuho

March 30, 2023 | markets.businessinsider.com

Immatics (IMTX) Initiated with a Buy at Mizuho Securities

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Company Calendar

Last Earnings: 3/21/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMTX
CUSIP: N/A
CIK: 1809196
Web: www.immatics.com
Phone: 4.97072E+12
Fax: N/A
Employees: 188
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.75
High Stock Price Forecast: $26.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +100.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $39.53 million
Net Margins: -85.93%
Pretax Margin: -88.57%
Return on Equity: -41.31%
Return on Assets: -17.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.43
Quick Ratio: 3.43

Sales & Book Value

Annual Sales: $182.13 million
Price / Sales: 4.15
Cash Flow: $0.61 per share
Price / Cash Flow: 16.11
Book Value: $2.80 per share
Price / Book: 3.53

Miscellaneous

Outstanding Shares: 76,670,000
Free Float: N/A
Market Cap: $756.73 million
Optionable: Not Optionable
Beta: 0.44

Key Executives

Dr. Harpreet Singh Ph.D. (Age 47)
CEO, MD, Member of Management Board & Supervisory Director

Dr. Hans-Georg Rammensee Ph.D.
Co-Founder & Member of the Scientific Advisory Board

Dr. Toni Weinschenk Ph.D. (Age 49)
Co-Founder & Chief Innovation Officer

Mr. Arnd Christ MBA (Age 56)
Chief Financial Officer

Mr. Steffen Walter Ph.D. (Age 46)
Chief Technology Officer

Mr. Edward A. Sturchio
Gen. Counsel & Sec.

Ms. Anja Heuer B.Sc.
Director of Corp. Communications

Ms. Tamara Louw M.B.A.
P.H.R., Sr. Director of HR

Dr. Carsten Reinhardt M.D. (Age 55)
Ph.D., Chief Devel. Officer

Dr. Rainer Kramer Ph.D. (Age 57)
Chief Bus. Officer & Site Head Munich

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IMTX Stock - Frequently Asked Questions

Should I buy or sell Immatics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings or view top-rated stocks.
What is Immatics' stock price forecast for 2023?: 4 equities research analysts have issued 12 month price targets for Immatics' stock. Their IMTX share price forecasts range from $12.00 to $26.00. On average, they expect the company's stock price to reach $19.75 in the next year. This suggests a possible upside of 100.1% from the stock's current price.
View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts.
How have IMTX shares performed in 2023?: Immatics' stock was trading at $8.71 at the start of the year. Since then, IMTX stock has increased by 13.3% and is now trading at $9.87.
View the best growth stocks for 2023 here.
Are investors shorting Immatics?: Immatics saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,420,000 shares, an increase of 28.1% from the April 30th total of 3,450,000 shares. Based on an average trading volume of 370,900 shares, the days-to-cover ratio is currently 11.9 days. Currently, 8.1% of the company's stock are sold short.
View Immatics' Short Interest.
When is Immatics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our IMTX earnings forecast.
How were Immatics' earnings last quarter?: Immatics (NASDAQ:IMTX) issued its earnings results on Tuesday, March, 21st. The company reported ($0.23) earnings per share (EPS) for the quarter. The company earned $38.44 million during the quarter, compared to analysts' expectations of $13.18 million. Immatics had a negative net margin of 85.93% and a negative trailing twelve-month return on equity of 41.31%.
What ETFs hold Immatics' stock?: ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC),

What other stocks do shareholders of Immatics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).
What is Immatics' stock symbol?: Immatics trades on the NASDAQ under the ticker symbol "IMTX."
Who are Immatics' major shareholders?: Immatics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (7.87%), Price T Rowe Associates Inc. MD (0.77%), Braidwell LP (0.42%), JPMorgan Chase & Co. (0.29%), Hudson Bay Capital Management LP (0.28%) and Governors Lane LP (0.17%).
How do I buy shares of Immatics?: Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Immatics' stock price today?: One share of IMTX stock can currently be purchased for approximately $9.87.
How much money does Immatics make?: Immatics (NASDAQ:IMTX) has a market capitalization of $756.73 million and generates $182.13 million in revenue each year. The company earns $39.53 million in net income (profit) each year or ($1.06) on an earnings per share basis.
How many employees does Immatics have?: The company employs 188 workers across the globe.
How can I contact Immatics?: Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 4.97072E+12.

This page (NASDAQ:IMTX) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial